IRWD IRONWOOD PHARMACEUTICALS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1446847 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY18.1%
TTM net income YoY424.1%
TTM EPS YoY400.0%
Revenue 3-yr CAGR-2.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin62.9%
Net margin37.4%
FCF margin—
EBITDA margin63.2%
Returns
ROE—
ROA43.6%
ROIC (approx.)—
Asset turnover1.17x
Leverage & solvency
Liabilities / assets133.4%
Debt / equity—
Current ratio6.51x
Interest coverage8.28x
Cash quality & payout
Operating cash flow / net income1.37x
Accruals ratio-16.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $296.15M | $351.41M |
| R&D expense | $95.14M | $111.42M |
| SG&A expense | $82.26M | $144.27M |
| Operating income | $98.50M | $93.12M |
| Interest expense | $32.75M | $33.03M |
| Pretax income | $70.03M | $65.20M |
| Income tax | $46.01M | $64.32M |
| Net income | $24.02M | $880,000 |
| EBITDA | $99.60M | $94.32M |
| EPS (basic) | 0.15 | 0.01 |
| EPS (diluted) | 0.15 | 0.01 |
| Weighted avg. shares (diluted) | 162.98M | 160.08M |
| Balance sheet | ||
| Cash & equivalents | $215.46M | $88.56M |
| Receivables | $46.74M | $81.89M |
| Current assets | $274.18M | $182.37M |
| PP&E, net | $3.41M | $4.50M |
| Intangibles | $2.04M | $2.86M |
| Total assets | $396.90M | $350.91M |
| Current liabilities | $242.22M | $38.85M |
| Long-term debt | — | $198.99M |
| Total debt | — | $198.99M |
| Total liabilities | $658.74M | $652.24M |
| Shareholders' equity | -$261.83M | -$301.33M |
| Net debt | — | $110.43M |
| Shares outstanding | 163.06M | 160.21M |
| Cash flow statement | ||
| Operating cash flow | $127.04M | $103.55M |
| Capital expenditure | $34,000 | $142,000 |
| Free cash flow | $127.01M | $103.41M |
| Investing cash flow | -$34,000 | -$142,000 |
| Financing cash flow | $216,000 | -$106.97M |
| Depreciation & amortization | $1.10M | $1.20M |
| Stock-based compensation | $17.25M | $29.85M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.